Africa: Major Improvements in Quality of Life for People With Drug-Susceptible TB Expected Following Updates in TB Treatment Regimens

[WHO] Landmark changes in shortening treatment duration has been announced by WHO in its updated consolidated guidelines on treatment of drug-susceptible TB. The guidelines include a new recommendation for the use of a 4-month regimen composed of isoniazid, rifapentine, moxifloxacin and pyrazinamide for the treatment and care of DS-TB. The shorter and effective new regimen offers improved quality of life for people with TB.
Source: AllAfrica News: Tuberculosis - Category: Infectious Diseases Source Type: news